Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 04, 2023

BUY
$76.01 - $86.7 $500,145 - $570,486
6,580 New
6,580 $507,000
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $865,652 - $988,797
14,539 New
14,539 $8.97 Million
Q1 2022

May 16, 2022

SELL
$57.92 - $72.58 $202,893 - $254,247
-3,503 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$64.88 - $73.64 $227,274 - $257,960
3,503 New
3,503 $254,000
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $1.22 Million - $1.39 Million
-20,269 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$56.65 - $64.55 $269,427 - $306,999
4,756 Added 30.66%
20,269 $1.18 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $567,097 - $713,026
9,132 Added 143.11%
15,513 $974,000
Q2 2020

Aug 14, 2020

BUY
$72.34 - $84.0 $461,601 - $536,004
6,381 New
6,381 $491,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.